Phosphodiesterase inhibitors as potential cognition enhancing agents

Current Topics in Medicinal Chemistry

Volumn 10, Issue 2, 2010, Pages 222-230

  Schmidt, Christopher J ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC NUCLEOTIDE; NOOTROPIC AGENT; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; SPLEEN EXONUCLEASE;

CELL COMMUNICATION; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; DRUG MECHANISM; DRUG TARGETING; HUMAN; NONHUMAN; REVIEW;

ANTIPSYCHOTIC AGENTS; COGNITION; COGNITION DISORDERS; HUMANS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77949362910     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610790411009     Document Type: Review

References (66)

1. Goraya, T. A.; Cooper, D. M. Ca2+-calmodulin-dependent phosphodiesterase (PDE1): current perspectives. Cell Signal, 2005, 17, 789-797.
2. Bender, A. T.; Beavo, J. A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev., 2006, 58, 488-520.
3. Menniti, F. S.; Faraci, W. S.; Schmidt, C. J. Phosphodiesterases in the CNS: targets for drug development. Nat. Rev. Drug Discov., 2006, 5, 660-670.
4. Lugnier, C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol. Ther., 2006, 109, 366-398.
5. Ghavami, A.; Hirst, W. D.; Novak, T. J. Selective phosphodiesterase (PDE)-4 inhibitors: a novel approach to treating memory deficit? Drugs R D, 2006, 7, 63-71.
6. Puzzo, D.; Sapienza, S.; Arancio, O.; Palmeri, A. Role of phosphodiesterase 5 in synaptic plasticity and memory. Neuropsychiatr Dis. Treat., 2008, 4, 371-387.
7. Reneerkens, O. A.; Rutten, K.; Steinbusch, H. W.; Blokland, A.; Prickaerts, J. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology, (Berl) 2009, 202, 419-443.
8. Bales, K.R.; Menniti, F.S. Promoting synaptic resilience in Alzheimer's disease patients through PDE inhibition. In: Emerging Drugs and Targets for AD. Martinez, A., Ed, Springer, in press 2009.
9. Rodefer, J. S.; Murphy, E. R.; Baxter, M. G. PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur. J. Neurosci., 2005, 21, 1070-1076.
10. Grauer, S. M.; Pulito, V. L.; Navarra, R. L.; Kelly, M. P.; Kelley, C.; Graf, R.; Langen, B.; Logue, S.; Brennan, J.; Jiang, L.; Charych, E.; Egerland, U.; Liu, F.; Marquis, K. L.; Malamas, M.; Hage, T.; Comery, T. A.; Brandon, N. J. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J. Pharmacol. Exp. Ther., 2009, 331, 574-590.
11. Schmidt, C. J.; Chapin, D. S.; Cianfrogna, J.; Corman, M. L.; Hajos, M.; Harms, J. F.; Hoffman, W. E.; Lebel, L. A.; McCarthy, S. A.; Nelson, F. R.; Proulx-LaFrance, C.; Majchrzak, M. J.; Ramirez, A. D.; Schmidt, K.; Seymour, P. A.; Siuciak, J. A.; Tingley, F. D., 3rd; Williams, R. D.; Verhoest, P. R.; Menniti, F. S. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J. Pharmacol. Exp. Ther., 2008, 325, 681-690.
12. Sadana, R.; Dessauer, C. W. Physiological roles for G proteinregulated adenylyl cyclase isoforms: insights from knockout and overexpression studies. Neurosignals, 2009, 17, 5-22.
13. Garbers, D. L.; Chrisman, T. D.; Wiegn, P.; Katafuchi, T.; Albanesi, J. P.; Bielinski, V.; Barylko, B.; Redfield, M. M.; Burnett, J. C., Jr. Membrane guanylyl cyclase receptors: an update. Trends Endocrinol. Metab., 2006, 17, 251-258.
14. Biel, M. Cyclic nucleotide-regulated cation channels. J. Biol. Chem., 2009, 284, 9017-9021.
15. Borland, G.; Smith, B. O.; Yarwood, S. J. EPAC proteins transduce diverse cellular actions of cAMP. Br. J. Pharmacol., 2009, 158, 70-86.
16. Dessauer, C. W. Adenylyl cyclase-a-kinase anchoring protein complexes: the next dimension in cAMP signaling. Mol. Pharmacol., 2009, 76, 935-941.
17. Baillie, G. S. Compartmentalized signalling: spatial regulation of cAMP by the action of compartmentalized phosphodiesterases. FEBS J., 2009, 276, 1790-1799.
18. Pandit ,J.; Forman, M.D.; Fennell, K.F.; Dillman, K.S.; Menniti, F.S.Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full length construct. Proc. Natl. Acad. Sci. USA, 2009, 106(43), 18225-8230.
19. Beavo, J. A.; Francis, S. H.; Houslay, M. D. Cyclic Nucleotide Phosphodiesterases in Health and Disease; CRC Press: USA, 2006.
20. Zakzanis, K. K. Quantitative evidence for neuroanatomic and neuropsychological markers in dementia of the Alzheimer's type. J. Clin. Exp. Neuropsychol., 1998, 20, 259-269.
21. Heinrichs, R. W.; Zakzanis, K. K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology, 1998, 12, 426-245.
22. Zakzanis, K. K.; Leach, L.; Kaplan, E. On the nature and pattern of neurocognitive function in major depressive disorder. Neuropsychiatry Neuropsychol. Behav. Neurol., 1998, 11, 111-119.
23. Holtmaat, A.; Svoboda, K. Experience-dependent structural synaptic plasticity in the mammalian brain. Nat. Rev. Neurosci., 2009, 10, 647-658.
24. Citri, A.; Malenka, R. C. Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology, 2008, 33, 18-41.
25. Lee, Y. S.; Silva, A. J. The molecular and cellular biology of enhanced cognition. Nat. Rev. Neurosci., 2009, 10, 126-140.
26. Dere, E.; Huston, J. P.; De Souza Silva, M. A. The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci. Biobehav. Rev., 2007, 31, 673-704.
27. Polli, J. W.; Kincaid, R. L. Molecular cloning of DNA encoding a calmodulin-dependent phosphodiesterase enriched in striatum. Proc. Natl . Acad. Sci. USA, 1992, 89, 11079-11083.
28. Xie, Z.; Adamowicz, W. O.; Eldred, W. D.; Jakowski, A. B.; Kleiman, R. J.; Morton, D. G.; Stephenson, D. T.; Strick, C. A.; Williams, R. D.; Menniti, F. S. Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience, 2006, 139, 597-607.
29. Reed, T. M.; Repaske, D. R.; Snyder, G. L.; Greengard, P.; Vorhees, C. V. Phosphodiesterase 1B knock-out mice exhibit exaggerated locomotor hyperactivity and DARPP-32 phosphorylation in response to dopamine agonists and display impaired spatial learning. J. Neurosci., 2002, 22, 5188-5197.
30. Ehrman, L. A.; Williams, M. T.; Schaefer, T. L.; Gudelsky, G. A.; Reed, T. M.; Fienberg, A. A.; Greengard, P.; Vorhees, C. V. Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP32-dependent pathways: evidence from PDE1BDARPP32 double-knockout mice. Genes Brain Behav., 2006, 5, 540-551.
31. Stramiello, M.; Wagner, J. J. D1/5 receptor-mediated enhancement of LTP requires PKA, Src family kinases, and NR2B-containing NMDARs. Neuropharmacology, 2008, 55, 871-877.
32. Granado, N.; Ortiz, O.; Suarez, L. M.; Martin, E. D.; Cena, V.; Solis, J. M.; Moratalla, R. D1 but not D5 dopamine receptors are critical for LTP, spatial learning, and LTP-Induced arc and zif268 expression in the hippocampus. Cereb. Cortex., 2008, 18, 1-12.
33. Giorgi, M.; D'Angelo, V.; Esposito, Z.; Nuccetelli, V.; Sorge, R.; Martorana, A.; Stefani, A.; Bernardi, G.; Sancesario, G. Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. Eur. J. Neurosci., 2008, 28, 941-950.
34. Deshmukh, R.; Sharma, V.; Mehan, S.; Sharma, N.; Bedi, K. L. Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine - a PDE1 inhibitor. Eur. J. Pharmacol., 2009, 620, 49-56.
35. Russwurm, C.; Zoidl, G.; Koesling, D.; Russwurm, M. Dual acylation of PDE2A splice variant 3: targeting to synaptic membranes. J. Biol. Chem., 2009, 284, 25782-25790.
36. Martinez, S. E.; Beavo, J. A.; Hol, W. G. GAF domains: two-billion-year-old molecular switches that bind cyclic nucleotides. Mol. Interv., 2002, 2, 317-323.
37. Jager, M.; Russwurm, C.; Koesling, D.; Russwurm, M. GAF domain-induced activation of phosphodiesterase 2 and 5. BMC Pharmacology, 2009, 9(Suppl 1), P28.
38. Nikolaev, V. O.; Gambaryan, S.; Engelhardt, S.; Walter, U.; Lohse, M. J. Real-time monitoring of the PDE2 activity of live cells: hormone-stimulated cAMP hydrolysis is faster than hormonestimulated cAMP synthesis. J. Biol. Chem., 2005, 280, 1716-1719.
39. Stephenson, D. T.; Coskran, T. M.; Wilhelms, M. B.; Adamowicz, W. O.; O'Donnell, M. M.; Muravnick, K. B.; Menniti, F. S.; Kleiman, R. J.; Morton, D. Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species. J. Histochem. Cytochem., 2009, 57, 933-949.
40. Kobayashi, K. Targeting the hippocampal mossy fiber synapse for the treatment of psychiatric disorders. Mol. Neurobiol., 2009, 39, 24-36.
41. Suvarna, N. U.; O'Donnell, J. M. Hydrolysis of N-methyl-Daspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus. J. Pharmacol. Exp. Ther., 2002, 302, 249-256.
42. Boess, F. G.; Hendrix, M.; van der Staay, F. J.; Erb, C.; Schreiber, R.; van Staveren, W.; de Vente, J.; Prickaerts, J.; Blokland, A.; Koenig, G. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology, 2004, 47, 1081-1092.
43. van Donkelaar, E. L.; Rutten, K.; Blokland, A.; Akkerman, S.; Steinbusch, H. W.; Prickaerts, J. Phosphodiesterase 2 and 5 inhibition attenuates the object memory deficit induced by acute tryptophan depletion. Eur. J. Pharmacol., 2008, 600, 98-104.
44. Domek-Lopacinska, K.; Strosznajder, J. B. The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging. Brain Res., 2008, 1216, 68-77.
45. Masood, A.; Nadeem, A.; Mustafa, S. J.; O'Donnell, J. M. Reversal of oxidative stress-induced anxiety by inhibition of phosphodiesterase-2 in mice. J. Pharmacol .Exp. Ther., 2008, 326, 369-379.
46. Monti, B.; Contestabile, A. Memory-enhancing drugs: a molecular perspective. Mini Rev. Med. Chem., 2009, 9, 769-781.
47. Perez-Torres, S.; Miro, X.; Palacios, J. M.; Cortes, R.; Puigdomenech, P.; Mengod, G. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography. Com parison with monkey and rat brain. J. Chem. Neuroanat., 2000, 20, 349-374.
48. Halene, T. B.; Siegel, S. J. PDE inhibitors in psychiatry - future options for dementia, depression and schizophrenia? Drug Discov. Today, 2007, 12, 870-878.
49. Siuciak, J. A.; Chapin, D. S.; McCarthy, S. A.; Martin, A. N. Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology (Berl), 2007, 192, 415-424.
50. Rutten, K.; Prickaerts, J.; Schaenzle, G.; Rosenbrock, H.; Blokland, A. Sub-chronic rolipram treatment leads to a persistent improvement in long-term object memory in rats. Neurobiol. Learn Mem., 2008, 90, 569-575.
51. Millar, J. K.; Mackie, S.; Clapcote, S. J.; Murdoch, H.; Pickard, B. S.; Christie, S.; Muir, W. J.; Blackwood, D. H.; Roder, J. C.; Houslay, M. D.; Porteous, D. J. Disrupted in schizophrenia 1 and phosphodiesterase 4B: towards an understanding of psychiatric illness. J. Physiol., 2007, 584, 401-5.
52. Rutten, K.; Prickaerts, J.; Hendrix, M.; van der Staay, F. J.; Sik, A.; Blokland, A. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. Eur. J. Pharmacol., 2007, 558, 107-112.
53. Spina, D. PDE4 inhibitors: current status. Br. J. Pharmacol., 2008, 155, 308-15.
54. Robichaud, A.; Stamatiou, P. B.; Jin, S. L.; Lachance, N.; MacDonald, D.; Laliberte, F.; Liu, S.; Huang, Z.; Conti, M.; Chan, C. C. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J. Clin. Invest, 2002, 110, 1045-1052.
55. Cherry, J. A.; Davis, R. L. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J. Comp. Neurol., 1999, 407, 287-2301.
56. Menniti, F. S.; Ren, J.; Coskran, T. M.; Liu, J.; Morton, D. G.; Sietsma, D. K.; Som, A.; Stephenson, D. T.; Tate, B. A.; Finklestein, S. P. PDE5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism. J. Pharmacol. Exp. Ther., 2009, 331(3), 842-850.
57. Rutten, K.; Basile, J. L.; Prickaerts, J.; Blokland, A.; Vivian, J. A. Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques. Psychopharmacology (Berl), 2008, 196, 643-648.
58. Puzzo, D.; Vitolo, O.; Trinchese, F.; Jacob, J. P.; Palmeri, A.; Arancio, O. Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP- responsive element-binding protein pathway during hippocampal synaptic plasticity. J. Neurosci., 2005, 25, 6887-6897.
59. Puzzo, D.; Staniszewski, A.; Deng, S. X.; Privitera, L.; Leznik, E.; Liu, S.; Zhang, H.; Feng, Y.; Palmeri, A.; Landry, D. W.; Arancio, O. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model. J. Neurosci., 2009, 29, 8075-8086.
60. Rutten, K.; Van Donkelaar, E. L.; Ferrington, L.; Blokland, A.; Bollen, E.; Steinbusch, H. W.; Kelly, P. A.; Prickaerts, J. H. Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats. Neuropsychopharmacology, 2009, 34, 1914-1925.
61. Goff, D. C.; Cather, C.; Freudenreich, O.; Henderson, D. C.; Evins, A. E.; Culhane, M. A.; Walsh, J. P. A placebo-controlled study of sildenafil effects on cognition in schizophrenia. Psychopharmacology (Berl), 2009, 202, 411-417.
62. Fisher, D. A.; Smith, J. F.; Pillar, J. S.; St Denis, S. H.; Cheng, J. B. Isolation and characterization of PDE9A, a novel human cGMPspecific phosphodiesterase. J. Biol. Chem., 1998, 273, 15559-15564.
63. Andreeva, S. G.; Dikkes, P.; Epstein, P. M.; Rosenberg, P. A. Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain. J. Neurosci., 2001, 21, 9068-9076.
64. Reyes-Irisarri, E.; Markerink-Van Ittersum, M.; Mengod, G.; de Vente, J. Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains. Eur. J. Neurosci., 2007, 25, 3332-3338.
65. van der Staay, F. J.; Rutten, K.; Barfacker, L.; Devry, J.; Erb, C.; Heckroth, H.; Karthaus, D.; Tersteegen, A.; van Kampen, M.; Blokland, A.; Prickaerts, J.; Reymann, K. G.; Schroder, U. H.; Hendrix, M. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology, 2008, 55, 908-918.
66. Schmidt, C. J.; Harms, J. F.; Tingley, F. D.; Schmidt, K.; Adamowicz, W. O.; Romegialli, A.; Kleiman, R. J.; Barry, C. J.; Coskran, T. M.; O'Neill, S. M. PDE9A-mediated regulation of cGMP: Developing a biomarker for a novel therapy for Alzheimer's disease. Alzheimer's Dementia, 2009, 5, 331-331.